Nuvalent
preliminary activity phase induced tumor response across heavily patient populations radiographic tumor regression observed across all dose levels data as of for response evaluable patients with treated by central nervous system not evaluable objective response rate progressive disease partial response once daily response evaluation criteria in solid version stable disease tyrosine kinase inhibitor footnotes for waterfall two patients and dose cohorts both with prior therapies consisting of and chemotherapy not shown due to incomplete or missing post tumor assessments in the setting of and symptomatic deterioration single not confirmed ongoing partial responses pending confirmation best response due to residual disease additional prior was including and investigational therapy source a patients with a best response all response evaluable resistance mutation history of metastases prior and prior or chemotherapy a includes ongoing partial responses pending confirmation includes ongoing partial response pending confirmation patient discontinued treatment due to clinical progression without post radiographic assessment these prior were discontinued due to progressive disease in patients key be dose level cohort prior prior lines chemotherapy prior lines anticancer therapy liss us us | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
33 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preliminary activity radiographic tumor response in patients with and without known alk resistance mutations phase no mutation single or compound mutation a key i dose level cohort prior a prior lines chemotherapy prior lines anticancer therapy data cut off august response evaluable four response evaluable no single or compound not shown due to incomplete or missing post assessments the setting of or symptomatic deterioration mutation as per any prior local testing or central analyses progressive disease partial once daily stable disease tyrosine kinase inhibitor evidence of allelic configuration mutation variant of unknown significance ongoing partial responses pending confirmation single not confirmed additional was including investigational therapy source lin i i | Nuvalent
Investor Presentation
February 2024
preliminary activity phase induced tumor response across heavily patient populations radiographic tumor regression observed across all dose levels data as of for response evaluable patients with treated by central nervous system not evaluable objective response rate progressive disease partial response once daily response evaluation criteria in solid version stable disease tyrosine kinase inhibitor footnotes for waterfall two patients and dose cohorts both with prior therapies consisting of and chemotherapy not shown due to incomplete or missing post tumor assessments in the setting of and symptomatic deterioration single not confirmed ongoing partial responses pending confirmation best response due to residual disease additional prior was including and investigational therapy source a patients with across all dose levels best response all response evaluable resistance mutation history of metastases prior and chemotherapy prior or i includes ongoing partial responses pending confirmation includes ongoing partial response pending confirmation patient discontinued treatment due to clinical progression without post radiographic assessment these prior were discontinued due to progressive disease in patients key i a i a dose level cohort prior prior lines chemotherapy prior lines anticancer therapy a | Nuvalent
Investor Presentation
February 2024
preliminary activity radiographic tumor response in patients with and without known alk resistance mutations phase no mutation single or compound mutation key so as a dose level cohort prior prior lines chemotherapy prior lines anticancer therapy i data cut off august response evaluable four response evaluable no single or compound not shown due to incomplete or missing post assessments the setting of or symptomatic deterioration mutation as per any prior local testing or central analyses progressive disease partial once daily stable disease tyrosine kinase inhibitor evidence of allelic configuration mutation variant of unknown significance ongoing partial responses pending confirmation single not confirmed additional was including investigational therapy source lin i i | Nuvalent
Investor Presentation
January 2024
preliminary activity phase induced tumor response across heavily patient populations radiographic tumor regression observed across all dose levels data as of for response evaluable patients with treated by central nervous system not evaluable objective response rate progressive disease partial response once daily response evaluation criteria in solid version stable disease tyrosine kinase inhibitor footnotes for waterfall two patients and dose cohorts both with prior therapies consisting of and chemotherapy not shown due to incomplete or missing post tumor assessments in the setting of and symptomatic deterioration not confirmed ongoing partial responses pending confirmation best response due to residual disease additional prior was including and investigational therapy patients with across all dose levels best response all response evaluable resistance mutation history of metastases prior and chemotherapy prior or includes ongoing partial responses pending confirmation includes ongoing partial response pending confirmation patient discontinued treatment due to clinical progression without post radiographic assessment these prior were discontinued due to progressive disease in patients key a a source a prior lines anticancer therapy i a a dose level cohort prior prior lines chemotherapy a | Nuvalent
Related slides by other companies
Genelux
Investor Presentation
December 2023
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
October 2023
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
February 2024
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
July 2023
demonstrated deep and durable tumor shrinkage | Genelux
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io